New York State Teachers Retirement System Sells 4,038 Shares of STAAR Surgical (NASDAQ:STAA)

New York State Teachers Retirement System cut its stake in STAAR Surgical (NASDAQ:STAA) by 7.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 54,016 shares of the medical instruments supplier’s stock after selling 4,038 shares during the quarter. New York State Teachers Retirement System’s holdings in STAAR Surgical were worth $1,312,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the business. Arcadia Investment Management Corp MI purchased a new position in shares of STAAR Surgical in the third quarter worth $37,000. Quarry LP bought a new position in STAAR Surgical during the 3rd quarter worth about $50,000. Quest Partners LLC purchased a new stake in shares of STAAR Surgical during the third quarter valued at about $128,000. Van ECK Associates Corp raised its position in shares of STAAR Surgical by 12.7% in the 3rd quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier’s stock valued at $129,000 after purchasing an additional 393 shares during the last quarter. Finally, Larson Financial Group LLC increased its holdings in STAAR Surgical by 78.3% in the 3rd quarter. Larson Financial Group LLC now owns 4,863 shares of the medical instruments supplier’s stock worth $181,000 after buying an additional 2,135 shares during the period. 96.70% of the stock is currently owned by institutional investors.

STAAR Surgical Price Performance

NASDAQ STAA opened at $16.87 on Monday. The business’s 50-day simple moving average is $22.47 and its 200-day simple moving average is $28.05. The firm has a market capitalization of $831.35 million, a P/E ratio of -41.15 and a beta of 0.62. STAAR Surgical has a 1-year low of $13.50 and a 1-year high of $52.68.

Insider Buying and Selling

In related news, major shareholder Broadwood Partners, L.P. acquired 36,532 shares of STAAR Surgical stock in a transaction that occurred on Friday, February 14th. The stock was acquired at an average price of $15.49 per share, for a total transaction of $565,880.68. Following the transaction, the insider now directly owns 11,289,437 shares of the company’s stock, valued at $174,873,379.13. This trade represents a 0.32 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders have purchased 402,024 shares of company stock valued at $6,936,904. Corporate insiders own 1.00% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on STAA. Piper Sandler dropped their price target on shares of STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 12th. Stephens reissued an “equal weight” rating and set a $28.00 price objective on shares of STAAR Surgical in a research report on Wednesday, February 12th. Stifel Nicolaus dropped their price target on shares of STAAR Surgical from $38.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, February 12th. StockNews.com downgraded STAAR Surgical from a “hold” rating to a “sell” rating in a report on Thursday, February 13th. Finally, Needham & Company LLC restated a “hold” rating on shares of STAAR Surgical in a research report on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, STAAR Surgical currently has an average rating of “Hold” and a consensus price target of $26.86.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.